The estimated Net Worth of John Markels is at least $2.63 mil dollars as of 14 June 2024. John Markels owns over 3,131 units of Sangamo Therapeutics Inc stock worth over $2,630 and over the last 5 years he sold SGMO stock worth over $0. In addition, he makes $0 as Independent Director at Sangamo Therapeutics Inc.
John has made over 2 trades of the Sangamo Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,131 units of SGMO stock worth $2,630 on 14 June 2024.
The largest trade he's ever made was buying 6,784 units of Sangamo Therapeutics Inc stock on 3 June 2022 worth over $25,033. On average, John trades about 1,102 units every 82 days since 2020. As of 14 June 2024 he still owns at least 3,131 units of Sangamo Therapeutics Inc stock.
You can see the complete history of John Markels stock trades at the bottom of the page.
Dr. John H. Markels Ph.D. serves as Independent Director of the Company. Dr. Markels has over 30 years of leadership experience in the pharmaceutical industry. Since January 2019, he has served as President of Global Vaccines at Merck & Co., Inc., or Merck, where he leads an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America from January 2018 to January 2019, SVP, Global Human Health Business Strategy from January 2017 to December 2017, Managing Director, Mexico from November 2013 to January 2017, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations and strategy, business development, alliance management, and supply chain. Dr. Markels received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware. The Nominating and Corporate Governance Committee and the Board believe that Dr. Markels’ extensive leadership experience in operations, strategy and development provides valuable operational, strategy and management skills to the Board.
John Markels is 54, he's been the Independent Director of Sangamo Therapeutics Inc since 2020. There are 10 older and 8 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.
John's mailing address filed with the SEC is 7000, Marina Boulevard, Brisbane, San Mateo County, California, 94005, United States.
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp y Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: